New York State Common Retirement Fund decreased its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 29.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 210,162 shares of the medical research company's stock after selling 86,213 shares during the period. New York State Common Retirement Fund owned approximately 0.11% of Exact Sciences worth $11,809,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of EXAS. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of Exact Sciences in the fourth quarter valued at approximately $478,000. Atria Wealth Solutions Inc. purchased a new position in shares of Exact Sciences during the 4th quarter worth $316,000. CIBC Asset Management Inc boosted its position in shares of Exact Sciences by 14.0% during the 4th quarter. CIBC Asset Management Inc now owns 7,396 shares of the medical research company's stock valued at $416,000 after acquiring an additional 907 shares during the last quarter. Sanctuary Advisors LLC grew its holdings in shares of Exact Sciences by 2.0% in the fourth quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company's stock valued at $763,000 after purchasing an additional 269 shares during the period. Finally, J.W. Cole Advisors Inc. increased its position in Exact Sciences by 14.3% during the fourth quarter. J.W. Cole Advisors Inc. now owns 8,582 shares of the medical research company's stock worth $482,000 after purchasing an additional 1,073 shares during the last quarter. 88.82% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several equities analysts have weighed in on EXAS shares. Scotiabank boosted their target price on shares of Exact Sciences from $70.00 to $73.00 and gave the company a "sector outperform" rating in a report on Monday. Citigroup lowered their price objective on Exact Sciences from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. Evercore ISI reduced their target price on Exact Sciences from $80.00 to $60.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 6th. TD Cowen upped their price target on Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Finally, William Blair reissued an "outperform" rating on shares of Exact Sciences in a research report on Thursday, February 20th. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $71.94.
Get Our Latest Report on EXAS
Exact Sciences Stock Down 0.9 %
Shares of NASDAQ:EXAS traded down $0.41 on Friday, hitting $47.41. 3,106,394 shares of the company's stock were exchanged, compared to its average volume of 2,339,565. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62. The company has a market capitalization of $8.81 billion, a PE ratio of -8.51 and a beta of 1.24. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. The firm's 50-day moving average is $54.17 and its 200 day moving average is $59.79.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The business had revenue of $713.42 million during the quarter, compared to analysts' expectations of $701.45 million. Sell-side analysts predict that Exact Sciences Co. will post -0.58 EPS for the current year.
Exact Sciences Company Profile
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Further Reading
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
